Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://www.ncbi.nlm.nih.gov/pubmed/27358844
http://dx.doi.org/10.1016/j.prnil.2016.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://www.ncbi.nlm.nih.gov/pubmed/27358844
http://dx.doi.org/10.1016/j.prnil.2016.02.002

Ejemplares similares